These results suggest that NAT2-guided dosing for slow acetylators would contribute to the preemptive discontinuation of anti-tuberculous drugs, thereby reducing the incidence of treatment failure and/or relapse of tuberculosis. This evidence concerns the gene NAT2 and tuberculosis.